Symbiosis Pharmaceutical Services
Stirling, UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
76.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (9)
Quick Facts: Symbiosis Pharmaceutical Services
- Signal Score
- 76.8/100 (as of 2026-04-29)
- Quality Compliance
- 100.0/100
- Headquarters
- Stirling, UK
- Modalities
- Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Symbiosis Pharmaceutical Services
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
MHRA GMP Certificates9 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Stirling, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Symbiosis Pharmaceutical Services FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-31 | Stirling | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Jul 05, 2026
Symbiosis Pharmaceutical Services MHRA GMP Compliance 9 certificates
2025-02
2025-02
2025-02
2025-02
2024-08
2024-08
2023-09
2023-09
2017-06
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 40211 Insp IMP 40211/405290-0019[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/405290-0020[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/37423042-0005[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/33209260-0005[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/33209260-0006[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [V] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK MIA 42671 Insp GMP 42671/13896012-0003[H] | COX PHARMACEUTICAL LIMITED | STIRLING FK7 7RP | 2017-06-01 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Jul 05, 2026
Frequently Asked Questions About Symbiosis Pharmaceutical Services
How many FDA inspections does Symbiosis Pharmaceutical Services have on record?
CDMO Signal tracks 1 FDA inspection for Symbiosis Pharmaceutical Services, sourced from the FDA inspection database. See the full inspection history above.
Has Symbiosis Pharmaceutical Services received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Symbiosis Pharmaceutical Services.
Does Symbiosis Pharmaceutical Services hold EMA or MHRA GMP certificates?
CDMO Signal tracks 9 MHRA GMP certificates for Symbiosis Pharmaceutical Services.
What is Symbiosis Pharmaceutical Services's CDMO Signal Score?
Symbiosis Pharmaceutical Services has a Signal Score of 77/100, based on quality, operations, financial stability, and capacity data.
Evaluating Symbiosis Pharmaceutical Services for a manufacturing program?
Use the free AI matchmaker to compare Symbiosis Pharmaceutical Services against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.2
CAR-T, Cell Therapy, iPSC, Gene Editing
eXmoor Pharma
Bristol, UK
Signal Score: 78.7
Cell Therapy, AAV
Ori Biotech
London, UK
Signal Score: 78.1
CAR-T, Cell Therapy
HiTech Health
London, UK
Signal Score: 76.8
Cell Therapy